Exclusive licensing grants Lilly development and commercialization rights for clazakizumab beyond ESKD-related cardiovascular prevention, while CSL retains the ESKD cardiovascular events indication.

Defensive investing doesn’t mean giving up long-term potential. The post If I had to build a defensive ASX share portfolio ...

Pain related to sickle cell disease (SCD) increases during menstruation, as do emergency department (ED) visits and hospitalizations, for many women and girls — according to a new, nationwide study ...

This might be a rare chance to pick up premium stocks at a steep discount. The post 2 ASX shares to buy today with $10,000 ...

I don’t blindly follow broker ratings, but when reasoning looks solid, I pay attention. These three ASX shares stand out The post Why these buy-rated ASX shares stand out to me appeared first on The ...

Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.

Fort Lauderdale, FL (May 2026)marcus evans announces The Evolution Summit, taking place May 7-8, 2026 at The Ritz-Carlton, Fort Lauderdale, Florida. Designed as an invitation-only, premium forum, the ...

In this video, Betty Hamilton, MD, provides a robust overview of the Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. She highlighted sessions focused on novel ...

Mordor Intelligence has published a new report on immunoglobulin market offering a comprehensive analysis of trends, growth drivers, and future projections.

Opportunities in the Sickle Cell Disease market include advancing gene-editing therapies like EDIT-301, expanding VOC-reducing treatments such as inclacumab, and exploring novel drug candidates like ...